

BioLamina appoints Brian Hawkins, PhD as new Chief Technology Officer (CTO).

Stockholm, March 3, 2025 – For immediate release

BioLamina AB, appoints Brian Hawkins as Chief Technology Officer and thereby strengthens its capabilities of accelerating stem-cell based therapies to patients

BioLamina AB, a leading provider of reagents for stem and primary cells, is pleased to announce the appointment of Brian Hawkins, PhD, as Chief Technology Officer (CTO).

Brian brings over 20 years of combined academic and corporate experience and is widely recognized as an authority in cell therapy manufacturing, induced Pluripotent Stem Cell (iPSC) development, and cryopreservation. He holds a PhD in Molecular Cell Biology and Biotechnology from Virginia Tech and completed his postdoctoral training at the University of Pennsylvania School of Medicine before becoming an assistant professor and founding member of the Mitochondria and Metabolism Center at the University of Washington School of Medicine.

Prior to joining BioLamina, Brian served as Chief Technology Officer at Pluristyx, where he played an important role in advancing iPSCs as a universal starting material for next generation clinical products. He has been an essential part of multiple national focus groups dedicated to progressing regenerative medicine and cell therapy, including leading the PDA/ANSI cryopreservation standard project recognized as a voluntary standard by the US FDA's Center for Biologics Evaluation and Research (CBER). Brian continues to contribute to the field through advisory roles at the Advanced Regenerative Manufacturing Institute (ARMI), Standards Coordinating Body, and ATMP Sweden working groups.

Brian Hawkins, Chief Technology Officer (CTO), comments:

"I look forward to working alongside the BioLamina team to form a dynamic partnership and strengthen BioLamina's global impact. We have a unique opportunity to continue existing collaborations, foster new relationships, solve challenges, and advance the field together with peers and partners. Our shared passion for science and innovation inspires me every day."

Klaus Langhoff-Roos, CEO, adds:

"We are excited to have Brian join us! He brings deep expertise and passion for the stem cell therapy space. He is highly respected across the field for his academic credentials, ability to bridge gaps between scientific challenges and commercial applications, and his proven track record in building biotech innovations from the ground up."

With Brian's appointment, BioLamina continues to strengthen its commitment to supporting researchers and industry partners in making the most of stem cell-based therapies and advanced cell models.



For inquiries, please contact

Klaus Langhoff-Roos, CEO

Phone: +46 76 495 19 63, e-mail: info@biolamina.com

About BioLamina and BioLaminin® technology

BioLamina is a biotechnology company with a scientific base and heritage in matrix biology and cell culture research. It supports scientists who have struggled for decades to grow pluripotent stem cells and other primary cells in the lab. By providing tools for efficient and easy cell culture, BioLamina aims to ease the path towards safe and effective cell therapies and make better cell assays and models for increasing accuracy in drug discovery and development. The power of Biolaminin® substrates, developed by BioLamina, has been demonstrated in numerous publications, and they will continue to provide vital support to the stem cell community—from scientific concepts to clinical studies. The company's main shareholders include Bure Equity AB (via Bure Growth), Lauxera Capital Partners, the Tryggvason family (the company's founders), and Northislet AB. For more information, please visit: <https://biolamina.com>

BioLamina AB - Löfströms Allé 5, SE-17266 Sundbyberg, Sweden

Email: info@biolamina.com

Org. nr. 556764-1872, VAT nr: SE556764187201